You are here: Knowledge Bank Press Releases

Press Releases

Press Releases is unique and effective promotional tool offered from aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.

To add free press releases please click here.

Jardiance® Demonstrated Cardiovascular (CV) Risk Reduction In People With Type 2 Diabetes At High Risk For CV Events

E-mail Print PDF

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events. EMPA-REG OUTCOME met its primary endpoint and demonstrated superiority of JARDIANCE, when added to standard of care, in CV risk reduction. The primary endpoint was defined as time to first occurrence of either CV death, or non-fatal myocardial infarction or non-fatal stroke.

Lilly's Humalog® 200 Units/ML KwikPen® Now Available In U.S. Pharmacies

E-mail Print PDF

First and only concentrated mealtime insulin analog may help people with diabetes fit their treatment into their daily lives Humalog® 200 units/mL KwikPen® (insulin lispro 200 units/mL; U-200), the first and only concentrated mealtime insulin analog in the U.S., is now available in pharmacies, Eli Lilly and Company (NYSE: LLY) announced today. Humalog U-200 KwikPen is a prefilled pen containing a concentrated formulation of Lilly's rapid-acting insulin Humalog® (insulin lispro 100 units/mL) to improve glycemic control in people with type 1 and type 2 diabetes. It is intended for people who are already taking mealtime insulin.

FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase

E-mail Print PDF

Seven-year study matches the longest duration of follow-up for any CML treatment, including imatinib, based on approved prescribing information

"We are proud to have generated this important five- and seven-year data in the first- and second-line treatment of CP Ph+ CML, as the findings further support the overall efficacy and safety profile of Sprycel over the long-term."

U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for Opdivo for the treatment of patients with previously untreated advanced melanoma. The company has taken the opportunity to submit additional data from the Opdivo clinical trial program to ensure the broadest data set, irrespective of BRAF status, was available for review. This submission constitutes a major amendment that will require additional time for review and the new FDA action date is November 27, 2015.

Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.

E-mail Print PDF

Company enters into a collaboration agreement with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute as part of the I-O RPM program

"Immunotherapy is rapidly evolving and has an enormous promise for cancer patients. This collaborative effort with Bristol-Myers Squibb will further strengthen our efforts to develop innovative new therapies against a wide variety of malignancies"

Bristol-Myers Squibb and The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testing and Awareness for Chronic Myeloid Leukemia Patients

E-mail Print PDF

"With the life expectancy of more CML patients increasing, the need for routine PCR testing is very important to ensure optimal treatment results"

Bristol-Myers Squibb Company (NYSE:BMY) today announced a charitable donation to The Leukemia & Lymphoma Society (LLS). The donation will provide financial assistance for chronic myeloid leukemia (CML) patients who need help paying for Polymerase Chain Reaction (PCR) testing, an important tool used in the diagnosis and monitoring of CML. The donation will also support LLS CML awareness activities focused on educating patients, caregivers and healthcare providers about the importance of continued monitoring with PCR testing.

Pall Purchases Exclusive License to Cutting-Edge Acoustic Wave Separation Technology from FloDesign Sonics for Biopharm Application

E-mail Print PDF

PORT WASHINGTON, N.Y. – June 15, 2015 – Pall Corporation, a global leader in filtration, separation and purification, announced the signing of an exclusive license for acoustic wave separation (AWS), a disruptive technology from FloDesign Sonics (FDS) for cell culture clarification for both fed-batch and perfusion applications. The AWS technology enables very-high-efficiency continuous removal of the cells in a closed system without centrifugation, thereby streamlining a challenging step in the biologics manufacturing process within a small operating footprint. The technology will complement Pall's industry-leading STAXTM depth filtration products to enable continuous clarification of cell culture, enabling integration of the bioreactor with downstream processing.

Venturing into chemicals in France

E-mail Print PDF

Invest in Grenoble-Isère and Rhône Valley - ACHEMA 2015 Hall 9.2, stand D41 Adisseo, Hexcel, Vencorex, Arkema… major international chemical industry stakeholders are investing more than a billion euros in Grenoble-Isère and the Rhône Valley (France).

ThyssenKrupp Uhde Chlorine Engineers and McPhy Energy seal a strategic commercial alliance in the area of hydrogen generation

E-mail Print PDF

McPhy Energy to become ThyssenKrupp Uhde Chlorine Engineers’ exclusive supplier for high-capacity, high-pressure hydrogen generation equipment for the carbon-free mobility and renewable energy sectors


E-mail Print PDF

AMPO, a leading foundry specialising in stainless steel and high alloy castings, with over 50 years’ experience, is an international company with a clear ability for innovation and developing processes, products and technologies.

Page 1 of 75

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »